HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

VGX-3100

targets E6 and E7 proteins of human papillomavirus

Networked: 5 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Dallas, Michael: 3 articles (01/2021 - 11/2015)
2.	Weiner, David B: 3 articles (01/2021 - 11/2015)
3.	Boyer, Jean: 2 articles (01/2021 - 11/2015)
4.	Bagarazzi, Mark L: 2 articles (01/2018 - 11/2015)
5.	Kraynyak, Kimberly A: 2 articles (01/2018 - 11/2015)
6.	Morrow, Matthew P: 2 articles (01/2018 - 11/2015)
7.	Sardesai, Niranjan Y: 2 articles (01/2018 - 11/2015)
8.	Sylvester, Albert J: 2 articles (01/2018 - 11/2015)
9.	Trimble, Cornelia L: 2 articles (01/2018 - 11/2015)
10.	Yan, Jian: 2 articles (01/2018 - 11/2015)

Related Diseases

1.	Uterine Cervical Dysplasia 01/01/2018 - "Purpose: As previously reported, treatment of high-grade cervical dysplasia with VGX-3100 resulted in complete histopathologic regression (CR) concomitant with elimination of HPV16/18 infection in 40.0% of VGX-3100-treated patients compared with only 14.3% in placebo recipients in a randomized phase IIb study. " 11/21/2015 - "Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial."
2.	Squamous Intraepithelial Lesions 01/01/2022 - "In 2014 and 2021, two nucleic-acid vaccine candidates named MAV E2 and VGX-3100 completed phase III clinical trials in Mexico and U.S., respectively, for patients with human papillomavirus (HPV)-related, high-grade squamous intraepithelial lesions (HSIL). " 01/01/2021 - "VGX-3100 is an investigational DNA-based immunotherapy being developed as an alternative to surgery and ablation for cervical High-Grade Squamous Intraepithelial Lesion (HSIL) with the aim of preserving reproductive health while treating precancerous disease. "
3.	Prostatic Neoplasms (Prostate Cancer) 11/10/2023 - "This brief discussion of vaccines and their varieties with examples also discusses vaccine clinical trials in relation to cancer diseases in this DNA and RNA-based cancer vaccine that has had successful clinical trials like the cervical cancer drug VGX-3100, the kidney cancer drug Pembrolizumab, MGN-1601, the prostate cancer drug pTVG-HP with rhGM-CSF, the melanoma cancer drug proteasome siRNA, and the lung cancer drug FRAME-001."
4.	Neoplasms (Cancer) 11/10/2023 - "This brief discussion of vaccines and their varieties with examples also discusses vaccine clinical trials in relation to cancer diseases in this DNA and RNA-based cancer vaccine that has had successful clinical trials like the cervical cancer drug VGX-3100, the kidney cancer drug Pembrolizumab, MGN-1601, the prostate cancer drug pTVG-HP with rhGM-CSF, the melanoma cancer drug proteasome siRNA, and the lung cancer drug FRAME-001."
5.	Melanoma (Melanoma, Malignant) 11/10/2023 - "This brief discussion of vaccines and their varieties with examples also discusses vaccine clinical trials in relation to cancer diseases in this DNA and RNA-based cancer vaccine that has had successful clinical trials like the cervical cancer drug VGX-3100, the kidney cancer drug Pembrolizumab, MGN-1601, the prostate cancer drug pTVG-HP with rhGM-CSF, the melanoma cancer drug proteasome siRNA, and the lung cancer drug FRAME-001."

Related Drugs and Biologics

1.	DNA (Deoxyribonucleic Acid)
2.	Proteasome Endopeptidase Complex (Proteasome)
3.	Small Interfering RNA (siRNA)
4.	Cancer Vaccines
5.	DNA Vaccines
6.	Vaccines
7.	RNA (Ribonucleic Acid)
8.	Proteins (Proteins, Gene)
9.	Nucleic Acid-Based Vaccines
10.	pembrolizumab

Related Therapies and Procedures

1.	Immunotherapy